Wieslab Diagnostic Services now offers a Tissue‑Based Assay (TBA) neuronal antibody screening service - one of the first of its kind in Europe. By reading immunofluorescent patterns directly in brain tissue, TBA gives a broad view of neuroinflammation and guides clinicians toward target‑specific confirmation and earlier, more confident diagnostic decisions in complex and time-sensitive neurological conditions.
What is TBA?
TBA is an immunofluorescence microscopy method performed on murine brain tissue sections. When a patient sample containing neuronal autoantibodies is introduced to this tissue, characteristic fluorescence patterns appear that reflect the distribution of target antigens within the tissue. These patterns provide an indication of the likely target at play, if any, which can then be followed up with an antigen‑specific confirmatory assay.
TBA can therefore be used to cast a wide net, delivering a comprehensive picture of neural antibody activity that guides the selection of a follow-up specific test. This clear two‑step path from broad screening to precise identification is vital in conditions where time and diagnostic confidence are critical.
Neuroimmune Diagnostics
Many distinct neuroimmune disorders begin with broad, fast‑evolving symptoms that can present very similarly to each other. Because a wide range of neuronal autoantibodies may be driving the illness, clinicians often face a crowded differential where several conditions fit the same early presentation, making a quick and accurate diagnosis difficult. This matters because many of these conditions progress rapidly, so delays - or pursuing the wrong treatment pathway - can lead to irreversible tissue injury and lasting loss of function.
TBA offers new diagnostic possibilities by providing a comprehensive first look that can reveal otherwise missed antibodies and direct the clinician toward the most relevant confirmatory test. By consolidating early investigative steps, TBA helps shorten the path to treatment decisions and reduces the risk of delayed or inappropriate care.
TBA vs Traditional Neuroimmune Diagnostics
Traditionally, neuronal autoantibody testing proceeds one target at a time. A clinician tests for the most likely antigen(s), and then - if findings are negative or incomplete - orders the next test in sequence. This stepwise approach is inherently limited to the antigens selected for testing, meaning relevant antibodies can be missed, leading to an increased risk of false positive and false negative diagnostic decisions. Further, each additional round of antibody screening adds time and resource demands which can delay effective treatment at precisely the moment when patients may need rapid intervention.
TBAs invert that sequence. Instead of testing one antigen at a time, TBA has the capacity to detect, in a single test, a wide panel of anti‑neuronal antibodies. This broad, pattern‑based screen then directs targeted, antigen‑specific confirmation only where indicated. Used together, this two‑step regimen improves overall sensitivity and specificity, helping to reduce both false negatives and false positives that can otherwise delay or misdirect treatment - an advantage that is especially important in complex, time‑critical neuroinflammatory presentations.
The result is a faster, more future‑ready pathway that saves valuable clinical time and lowers the risk of misdiagnosis, even as the catalogue of clinically relevant neuronal antibodies continues to expand.
.png?width=800&height=418&name=TBA%20workflow%20%20(1).png)
Exploratory and Confirmatory Testing
TBAs have value not just in initial diagnostics, but also in adjudication of existing patient diagnoses. As an exploratory screen in newly presenting patients, it can point clinicians toward the most appropriate antigen‑specific assay for precise identification. As a confirmatory (adjudication) tool later in the work‑up it can verify existing positive results based on the distinctive staining patten of the identified antibody or be used to challenge a standing diagnosis where clinicians have suspicion that relevant autoantibodies may have been missed or misidentified in prior testing.
Used in this complementary way, TBA helps clinicians validate or reconsider an initial diagnosis, reducing the chance of unnecessary treatment on the one hand and reducing treatment delays and the risk of irreversible tissue injury on the other.
By introducing TBA neuronal antibody screening Wieslab is providing a future‑ready, two‑step diagnostic regimen to simplify and improve the diagnostic process for neuroimmune conditions, offering a faster route to clarity when presentations are complex or time‑sensitive. For clinicians and researchers alike, TBA complements established single‑target assays, strengthens diagnostic confidence, and supports earlier, better‑targeted care for patients with suspected neuroinflammatory disease.
